Key Highlights
- $11.4M Series A funding led by Material Impact, with contributions from Prosus Ventures, In-Q-Tel, and others.
- Tierra Biosciences aims to revolutionize protein engineering with its high-throughput, AI-powered cell-free platform.
- Pioneering in AI and cell-free technology, Tierra enables rapid protein discovery and production, promising to overcome traditional bottlenecks in the bioeconomy.
Source: Business Wire
Notable Quotes
- “Tierra’s cell-free protein production platform will change the game, powering our customers’ discovery efforts with rapid access to large numbers of discrete custom proteins for screening and discovery, plus fast yield scale-up for downstream development and pilot work.” – Michael Nemzek, CEO at Tierra Biosciences
- “Tierra’s platform propels innovation in the bioeconomy by eliminating bottlenecks in protein discovery and manufacturing. We’re excited to partner with them as they fuse high-throughput manufacturing with artificial intelligence.” – Corinna Chen, Partner at Material Impact
- “Tierra’s cutting-edge platform, powered by advanced cell-free technology, is compelling in its ability to play a key role in building critical bio-infrastructure.” – Chenny Zhang, Principal, Investments at In-Q-Tel (IQT)
SoHC's Take
The significant funding round Tierra Biosciences has closed marks a pivotal moment in the field of protein synthesis. By integrating AI-guided cell-free technology, Tierra is not just innovating within the realms of biotechnology but is setting the stage for a major transformation across various critical sectors, including healthcare, agriculture, and industrial manufacturing. This approach not only accelerates the protein design-build-test-learn cycles but also democratizes access to custom proteins, potentially leading to breakthroughs in disease treatment, environmental sustainability, and food security. The involvement of high-profile investors underscores the confidence in Tierra Biosciences’ potential to lead this transformative journey, leveraging AI and cell-free platforms to unlock new possibilities beyond the natural limitations of traditional protein engineering.
